Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Islet cell tumor
Trial Status:  Active
Results 1-25 of 89 for your search:
Start Over
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSOM230B2412, NCT01794793
Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A-97-52030-270, NCT02075606
The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181215, NCT02282059
New Imaging Procedure for the Localisation of Insulinoma and Transplanted Islet Cells
Phase: Phase III, Phase II
Type: Diagnostic
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: EKBB 163/12, NCT02127541
A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PRODIGE31, NCT02288377
Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas
Phase: Phase III
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MKT-2012-nCLE-02, NCT01563133
177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: IJBMNLUMEN, 2012-003666-41, NCT01842165
Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced pNET
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 94
Sponsor: Other
Protocol IDs: GETNE1206, 2013-000726-66, NCT02246127
Efficacy and Safety of Radiofrequency Ablation in Pancreatic Neuroendocrine and Cystic Tumor
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 to 85
Sponsor: Other
Protocol IDs: RFAP, NCT02330497
Gallium-68 DOTATOC for Management of Neuroendocrine Tumors
Phase: Phase III
Type: Diagnostic, Health services research
Status: Approved-not yet active
Age: Not specified
Sponsor: Other
Protocol IDs: 15-999, NCT02375464
Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers
Phase: Phase II, Phase I
Type: Tissue collection/Repository
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 93-102, NCT00579163
Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NU 11I03, NCI-2011-02939, STU00053541, NCT01465659
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 andover
Sponsor: Other
Protocol IDs: 201303150, NCT01784861
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Phase: Phase II, Phase I
Type: Diagnostic
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 68Ga-DOTATATE, NCT02038738
Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors
Phase: Phase II, Phase I
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 092/11, NCT02078843
DOTA-TOC in Metastasized Neuroendocrine Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: MAW002, NCT00978211
Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: EudraCT 2006-004748-22, NCT01203306
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 78,256, NCT01237457
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-274, NCT01466036
Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NET0012, NCI-2011-03497, SU-10282011-8571, END0012, NCT01525082
Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HE 67/12, 2011-006160-48, NCT01648465
68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours
Phase: Phase II
Type: Diagnostic
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: 2012-000994-22, NCT01673906
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: E2211, NCI-2012-02007, U10CA021115, U10CA180820, NCT01824875
Temozolomide Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: TEPNET, NCT01845675
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
Phase: Phase II
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 130193, 13-C-0193, NCT01967537
Start Over